{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} The Promise of Lenvatinib/Pembrolizumab for Endometrial Cancer
Activity Steps
{{ evaluation.question.text }}
{{choice.text}}
{{evaluation.answerSet[0].text}}
Learning Objectives
After completing this continuing education activity you will be able to:
- Assess the results of the Phase III KEYNOTE-775/Study 309 trial evaluating the combination of pembrolizumab plus lenvatinib for the treatment of certain patients with endometrial cancer.
- Summarize the implications of the Phase III trial results for treatments strategies for women with gynecologic malignancies.
Learning Outcomes
Healthcare providers will demonstrate knowledge of current treatments for endometrial cancer by achieving a minimum score of 70% on the outcomes-based posttest.Disclosures
The author(s), faculty, staff, and planners in any position to control the content of this activity, have disclosed that they have no financial relationships with, or financial interests in, any commercial companies relevant to this educational activity.
Price:
$12.95
Credits:
- ANCC 1.0 CH
- DC - BON 1.0 CH
- FL - BON 1.0 CH
- GA - BON 1.0 CH
Lippincott Professional Development is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749. Lippincott Professional Development is also an approved provider of continuing nursing education by the District of Columbia Board of Nursing, Florida Board of Nursing, and Georgia Board of Nursing, #50-1223.
{{ evaluation.question.text }}
{{choice.text}}
{{evaluation.answerSet[0].text}}
Test Code: OT0821
Published: August 2021
Expires: 6/7/2024
Sources:
Oncology Times
Required Passing Score: 8/10 (80%)
Topics:
Gynecologic